TIGAR cooperates with glycolysis to inhibit leukemia cells apoptosis and predicts poor prognosis in

来源 :The 35th World Congress of the International Society of Hema | 被引量 : 0次 | 上传用户:lincl008
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background Recent studies has suggested that high levels of glycolytic metabolism in A ML blasts were associated with resistance to chemotherapy and pateintss survival.TP53-induced glycolysis and apoptosis regulator (TIGAR) inhibits glycolysis and promotes tum or cells survival.
其他文献
Backgroud Both peripheral blood (PB) and bone marrow (BM) can be used for molecular monitoring by quantitative real-time RT-PCR (Q-PCR) for chronic myeloid leukemia(CML).Aim To determine whether molec
会议
Objective Impaired megakaryocyte maturation and insufficient platelet production participate in the pathogenesis of primary immune thrombocytopenia (ITP).The demethylating agent,decitabine (DAC) has b
会议
Background CLL is one of the most common forms of leukemia among adults.Despite advances in the treatment of CLL,including chemotherapy,chemoimmunotherapy (CIT),and stem cell transplant (SCT),the dise
会议
Background Although chemoimmunotherapy regimens remain the standard in the initial treatment of younger,fit patients with CLL/SLL,relapses are typical.The treatment of older patients,patients with rel
会议
Background Chronic B lymphoproliferative diseases (BLPD),which are mainly compo sed of chronic lymphocytic leukemia (CLL),hairy cell leukemia (HCL),follicular lymphom a (FL),marginal zone lymphoma (MZ
会议
Background A recent GWAS analysis of B-cell chronic lymphocytic leukemia (CLL) identified 12 risk loci,some of which harbor apoptosis-related tumor suppressor genes.Herein we postulate that miR-3151,l
会议
Background The tumor suppressor TP53 is one of the most frequently altered genes in cancer.Several studies have shown TP53 mutations are frequently detected in patients with therapy-related AML or AML
会议
Introduction Donor cell neoplasms are rare complications of treatment regimens that involve stem cell transplantation for hematological malignancies,myelodysplastic processes,or certain genetic or met
会议
Background FLT3 mutation is found in about 30 %of acute myeloid leukemia (AML) patients and several FLT3 inhibitors are undergoing investigation,but clinical efficacies were lower than expected.In pre
会议
To clarify the prevalence and prognostic significance of c-KIT mutations in patients with core binding factor acute myeloid leukemia (CBF-AML),a total of 351 patients who were categorized into pediatr
会议